Price movement over the last 24 hours
Abeona Therapeutics Inc vs e l f Beauty Inc — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while e l f Beauty Inc trades at $72.99 (market cap $4.48B). The key difference: e l f Beauty Inc is far larger — about 12× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, e l f Beauty Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | ELF | |
|---|---|---|
Market Cap | $373.32M | $4.48B |
Sector | Health | Technology |
52-Week High | $7.23 | $146.67 |
52-Week Low | $4.17 | $49.57 |
Enterprise Value | $228.22M | $5.11B |
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ELF Beauty trades at $73.49, down 3.83% recently, but maintains a bullish technical outlook with strong support at $72. The company reported impressive earnings beats in recent quarters with Q4 2025 EPS of $1.24 beating expectations of $0.73. Revenue growth remains robust at $1.31 billion in 2025, though net margins are thin at 1.61%. Analyst sentiment is mixed with 46% buy ratings and a consensus price target of $72.82, slightly below current levels.
The stock faces valuation concerns with a high P/E of 173.68, but strong revenue growth and expansion into haircare and skincare categories provide upside potential. Key risks include tariff exposure and core brand momentum challenges. Institutional ownership trends and recent insider activity suggest cautious optimism as the company executes its diversification strategy.
Trailing returns across standard periods
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →e.l.f. Beauty is a leading cosmetics company offering high-quality, 100% vegan, and cruelty-free products. It is known for its affordable and prestige-quality makeup and skincare items for a diverse global audience.
Read more on ELF →